NAS:ILMN (USA) Also trade in: Austria Germany Mexico UK

Illumina Inc

$ 279.44 -9.14 (-3.17%)
Volume: 1,219,478 Avg Vol (1m): 1,258,522
Market Cap $: 41.08 Bil Enterprise Value $: 39.77 Bil
P/E (TTM): 44.36 P/B: 9.48
Earnings Power Value 42.56
Net Current Asset Value 10.31
Tangible Book 22.76
Projected FCF 78.33
Median P/S Value 228.67
Graham Number 56.8
Peter Lynch Value 117.81
DCF (FCF Based) 50.01
DCF (Earnings Based) 179.35
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.70
Cash-To-Debt range over the past 10 years
Min: 0.69, Med: 1.62, Max: 16544
Current: 1.7
0.69
16544
Equity-to-Asset 0.62
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.55, Max: 0.94
Current: 0.62
0.36
0.94
Debt-to-Equity 0.43
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.5, Max: 1.5
Current: 0.43
0
1.5
Debt-to-EBITDA 1.46
Debt-to-EBITDA range over the past 10 years
Min: 1.08, Med: 1.76, Max: 3.41
Current: 1.46
1.08
3.41
Interest Coverage 13.03
Interest Coverage range over the past 10 years
Min: 5.3, Med: 9.45, Max: 17.52
Current: 13.03
5.3
17.52
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.67
DISTRESS
GREY
SAFE
Beneish M-Score -2.51
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 29.44%
WACC 8.48%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 24.88
Operating Margin range over the past 10 years
Min: 17.88, Med: 23.11, Max: 28.47
Current: 24.88
17.88
28.47
Net Margin % 27.56
Net Margin range over the past 10 years
Min: 8.21, Med: 16.41, Max: 27.56
Current: 27.56
8.21
27.56
ROE % 24.90
ROE range over the past 10 years
Min: 7.62, Med: 17.54, Max: 29.32
Current: 24.9
7.62
29.32
ROA % 13.82
ROA range over the past 10 years
Min: 4.29, Med: 9.38, Max: 15.22
Current: 13.82
4.29
15.22
ROC (Joel Greenblatt) % 71.40
ROC (Joel Greenblatt) range over the past 10 years
Min: 56.69, Med: 78.88, Max: 133.65
Current: 71.4
56.69
133.65
3-Year Total Revenue Growth Rate 14.50
3-Year Revenue Growth Rate range over the past 10 years
Min: -1, Med: 21, Max: 156.2
Current: 14.5
-1
156.2
3-Year Total EBITDA Growth Rate 14.50
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 27.3, Max: 119.6
Current: 14.5
0
119.6
3-Year EPS w/o NRI Growth Rate 21.50
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 26.5, Max: 56.4
Current: 21.5
0
56.4

Ratios

Current vs industry vs history
PE Ratio (TTM) 44.36
PE Ratio range over the past 10 years
Min: 32.02, Med: 68.47, Max: 302.86
Current: 44.36
32.02
302.86
Forward PE Ratio 47.85
N/A
PE Ratio without NRI 44.36
PE without NRI range over the past 10 years
Min: 32.02, Med: 68.47, Max: 302.86
Current: 44.36
32.02
302.86
Price-to-Owner-Earnings 54.74
Price-to-Owner-Earnings range over the past 10 years
Min: 20.62, Med: 57.17, Max: 97.42
Current: 54.74
20.62
97.42
PB Ratio 9.48
PB Ratio range over the past 10 years
Min: 2.62, Med: 9.03, Max: 21.7
Current: 9.48
2.62
21.7
PS Ratio 12.29
PS Ratio range over the past 10 years
Min: 3.54, Med: 10.06, Max: 17.19
Current: 12.29
3.54
17.19
Price-to-Free-Cash-Flow 59.80
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.31, Med: 46.1, Max: 102.59
Current: 59.8
13.31
102.59
Price-to-Operating-Cash-Flow 44.90
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 10.31, Med: 33.13, Max: 344.72
Current: 44.9
10.31
344.72
EV-to-EBIT 36.65
EV-to-EBIT range over the past 10 years
Min: 17, Med: 40.1, Max: 133.1
Current: 36.65
17
133.1
EV-to-EBITDA 31.17
EV-to-EBITDA range over the past 10 years
Min: 12.6, Med: 32.6, Max: 83.3
Current: 31.17
12.6
83.3
EV-to-Revenue 11.68
EV-to-Revenue range over the past 10 years
Min: 2.8, Med: 9.9, Max: 17.4
Current: 11.68
2.8
17.4
PEG Ratio 1.61
PEG Ratio range over the past 10 years
Min: 0.67, Med: 1.93, Max: 13.47
Current: 1.61
0.67
13.47
Shiller PE Ratio 100.41
Shiller PE Ratio range over the past 10 years
Min: 99.02, Med: 190.29, Max: 3600
Current: 100.41
99.02
3600
Current Ratio 6.79
Current Ratio range over the past 10 years
Min: 0.99, Med: 3.93, Max: 60.21
Current: 6.79
0.99
60.21
Quick Ratio 6.10
Quick Ratio range over the past 10 years
Min: 0.87, Med: 3.67, Max: 60.21
Current: 6.1
0.87
60.21
Days Inventory 134.57
Days Inventory range over the past 10 years
Min: 111.78, Med: 133.48, Max: 147.41
Current: 134.57
111.78
147.41
Days Sales Outstanding 50.40
Days Sales Outstanding range over the past 10 years
Min: 50.4, Med: 61.29, Max: 86.41
Current: 50.4
50.4
86.41
Days Payable 47.86
Days Payable range over the past 10 years
Min: 47.86, Med: 64.5, Max: 93.62
Current: 47.86
47.86
93.62

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.50
3-Year Share Buyback Rate range over the past 10 years
Min: -13.1, Med: -4.3, Max: 0.3
Current: -0.5
-13.1
0.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 12.28
Price-to-Tangible-Book range over the past 10 years
Min: 1.16, Med: 8.44, Max: 424.09
Current: 12.28
1.16
424.09
Price-to-Projected-FCF 3.57
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.53, Med: 4.44, Max: 42.17
Current: 3.57
1.53
42.17
Price-to-DCF (Earnings Based) 1.56
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.89, Med: 3.51, Max: 7.44
Current: 1.56
1.89
7.44
Price-to-Median-PS-Value 1.22
Price-to-Median-PS-Value range over the past 10 years
Min: 0.4, Med: 1.02, Max: 66.74
Current: 1.22
0.4
66.74
Price-to-Peter-Lynch-Fair-Value 2.37
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.36, Med: 2.56, Max: 9.54
Current: 2.37
1.36
9.54
Price-to-Graham-Number 4.92
Price-to-Graham-Number range over the past 10 years
Min: 3.55, Med: 6.48, Max: 47.48
Current: 4.92
3.55
47.48
Earnings Yield (Joel Greenblatt) % 2.73
Earnings Yield (Greenblatt) range over the past 10 years
Min: 0.8, Med: 2.5, Max: 5.9
Current: 2.73
0.8
5.9
Forward Rate of Return (Yacktman) % 20.14
Forward Rate of Return range over the past 10 years
Min: -0.4, Med: 21.2, Max: 23.3
Current: 20.14
-0.4
23.3

» ILMN's 30-Y Financials

Financials (Next Earnings Date: 2019-10-23)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ILMN

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare XAMS:PHIA NYSE:IQV XSWX:LONN NAS:IDXX NYSE:A SHSE:603259 NYSE:LH NAS:DXCM NYSE:MTD NAS:EXAS NYSE:WAT NYSE:DGX TSE:6869 XTER:SRT3 NYSE:BIO XPAR:BIM NYSE:PKI NAS:GH NAS:ICLR NYSE:QGEN
Traded in other countries ILU.Germany 0J8Z.UK
Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina Inc is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, and MiniSeq, and iSeq product lines.

More Statistics

Revenue (TTM) (Mil) $ 3,404
EPS (TTM) $ 6.3
Beta 1.2
Volatility % 39.94
52-Week Range $ 268.62 - 380.76
Shares Outstanding (Mil) 147

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N